Allurion Technologies, Inc. earnings releases ALUR

Allurion Technologies, Inc. last reported quarterly results on Jan 12, 2026, for Q4 FY2025 (the quarter ended Dec 31, 2025): revenue of $3.6 million (-35.4% year over year) and diluted EPS of -$0.59. It usually reports 12–44 days after a quarter ends.

Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–44 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.

Released Quarter Revenue Net income Diluted EPS
Jan 12, 2026
12 days after quarter end
Q4 FY2025
ended Dec 31, 2025
4
-35.4%
-6
+37.2%
-0.59
+88.9%
Nov 12, 2025
43 days after quarter end
Q3 FY2025
ended Sep 30, 2025
3
-50.5%
-12
-236.0%
-1.53
-145.0%
Aug 7, 2025
38 days after quarter end
Q2 FY2025
ended Jun 30, 2025
3
-71.3%
-9
-12.2%
-1.28
+70.5%
May 14, 2025
44 days after quarter end
Q1 FY2025
ended Mar 31, 2025
6
-40.5%
-2
-175.2%
-0.31
-132.3%
Jan 8, 2025
8 days after quarter end
Q4 FY2024
ended Dec 31, 2024
6
-32.1%
-10
+55.1%
-5.29
+53.0%
Nov 13, 2024
44 days after quarter end
Q3 FY2024
ended Sep 30, 2024
5
-70.5%
9
+140.4%
3.40
+125.1%
Aug 13, 2024
44 days after quarter end
Q2 FY2024
ended Jun 30, 2024
12
-9.2%
-8
+62.2%
-4.34
+79.3%
Apr 30, 2024
30 days after quarter end
—
ended Mar 31, 2024
—
—
—

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
ALUR (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Natick, MA
SEC filer status
, Emerging growth company
SEC CIK
1964979
Former names
ALLURION TECHNOLOGIES HOLDINGS, INC. (until Aug 1, 2023)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.